The Peptide Innovation for Early Diabetes Treatment (PIONEER) programme consisted of eight phase 3, randomized, controlled clinical studies and showed that oral semaglutide reduces glycated haemoglobin (HbA1c) and body weight in patients with T2DM and has potential cardiovascular benefits [35,36,37,38,39,40,41,42]
This may be due to better body image, increased confidence, improved blood flow, and hormonal balance
A question remains as to whether this therapy is effective in patients with existing HFpEF or if its primary benefit lies in impacting risk factors and associated cardiovascular diseases that contribute to the development of HFpEF
Using more than the recommended dosage of NovoLog can lead to serious side effects
This approach helps minimize potential side effects while ensuring you receive the full benefits of NAD+ therapy
For healing and recovery, GHK-Cu can be paired with BPC-157 or Thymosin Beta-4 to promote wound repair, reduce inflammation, and accelerate wound healing
)
